BUPI – a long-acting lozenge with bupivacaine for pain relief of Oral Mucositis in cancer patients
Moberg Pharma and partners will further develop and commersialise BUPI - an innovative and superior long-acting treatment for cancer patients suffering from pain associated with Oral Mucositis (OM). BUPI will be evaluated in a phase III trial. The project will deliver a final product ready for registration and thereafter launch – with documented benefits for patients.
1 590 000.00€
Cytology, Cancerology, Oncology